Should of asked him how PMCB is ever going to fill the required patients needed for there wishful trial. Not that he a frigging clue would have still been a good laugh. Good luck finding patients who meet these qualifications set in the new trial design. If pmcb ever started trials their looking at 10 years+ easily. On the other hand it gives KW and gang plenty of time to dilute the crap out of the stock and make themselves a lot of $ at shareholders expense.
Future Trial enrollment: -The patients accepted into the trial must have pancreatic cancer that is inoperable, but that has not yet spread from the pancreas where it first started to another place in the body (metastatic cancer).
Well that wipes out 90%
These patients must also have tumors that no longer respond to the combination chemotherapy treatment of Abraxane® + gemcitabine and that have been on the treatment for a period of between four and six months.
[color=blue]So they no longer benefit from Abraxane after 4-6 months and we don't think it's now spread? There goes another 9.9%[color/b]
American Cancer Society The average life expectancy after diagnosis with metastatic disease is just three to six months.
According to (ACS) For all stages of pancreatic cancer combined, the one-year relative survival rate is 20%, and the five-year rate is 6%. These low survival rates are attributable to the fact that fewer than 20% of patients' tumors are confined to the pancreas at the time of diagnosis; in most cases, the malignancy has already progressed to the point where surgical removal is impossible.